ANP32A: A Potential Drug Target for Neurological Disorders (G8125)

Target Name: ANP32A

NCBI ID: G8125

ANP32A

ANP32A: A Potential Drug Target for Neurological Disorders

ANP32A (I1PP2A), a protein found in the brain, has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders. Its functions and interactions with other proteins have been extensively studied, providing insights into its potential role in the development and treatment of such conditions.

ANP32A is a member of the I1PP family, which includes several related proteins that play crucial roles in the regulation of intracellular signaling pathways. These proteins are involved in a variety of cellular processes, including modulating neurotransmitter release, generating electrical signals, and regulating protein interactions. The I1PP family is highly conserved across various species, suggesting a central role in the evolution of complex cellular processes.

ANP32A is a 21-kDa protein that is expressed in various tissues and cells, including the brain. Its primary function is to regulate the intracellular signaling pathway known as the cAMP/protein kinase (PKA) signaling pathway. This pathway is involved in the regulation of various cellular processes, including neuronal excitability, synaptic plasticity, and hormone signaling.

The ANP32A protein has been shown to play a crucial role in the regulation of neuronal excitability and synaptic plasticity. It is a critical regulator of the neurotransmitter release from axons and dendrites of neurons, which is critical for the modulation of neuronal excitability. ANP32A has been shown to interact with several other proteins involved in the regulation of intracellular signaling pathways, including cAMP-dependent protein kinases (PKA), voltage-gated ion channels (VGIC), and neurotransmitter receptors.

One of the key functions of ANP32A is its role in modulating the levels of intracellular cAMP, which is a critical signaling molecule involved in the regulation of various cellular processes. The cAMP signaling pathway is a highly regulated pathway that is involved in the regulation of neuronal excitability, synaptic plasticity, and hormone signaling. The ANP32A protein has been shown to play a crucial role in the regulation of cAMP levels by interacting with several proteins involved in the pathway, including the catalytic subunit of PKA (PkA2) and the regulatory subunit (Pka1).

In addition to its role in the regulation of cAMP levels, ANP32A has also been shown to play a critical role in the regulation of neuronal excitability. The ANP32A protein has been shown to interact with several voltage-gated ion channels (VGIC), including the N-methyl-D-aspartate (NMDA) receptor channel. The NMDAR channel is involved in the regulation of neuronal excitability and is a key modulator of synaptic plasticity. The ANP32A protein has been shown to play a crucial role in the regulation of NMDA receptor channel function by interacting with the channel's catalytic subunit (Ca2+-ATP-dependent Cl- channel) and the regulatory subunit (尾-adrenergic receptor).

The ANP32A protein has also been shown to play a critical role in the regulation of the release of neurotransmitters, including dopamine and GABA. These neurotransmitters are involved in the regulation of various cellular processes, including neuronal excitability, synaptic plasticity, and mood regulation. The ANP32A protein has been shown to interact with several neurotransmitter receptors, including the dopamine receptor (DAR1) and the GABA receptor (GABAR1).

In addition to its role in the regulation of neurotransmitter release, ANP32A has also been shown to play a critical role in the regulation of the degradation of neurotransmitters. The ANP32A protein has been shown to interact with several enzymes involved in the degradation of neurotransmitters, including the enzyme

Protein Name: Acidic Nuclear Phosphoprotein 32 Family Member A

Functions: Multifunctional protein that is involved in the regulation of many processes including tumor suppression, apoptosis, cell cycle progression or transcription (PubMed:16341127, PubMed:11360199, PubMed:18439902, PubMed:10400610). Promotes apoptosis by favouring the activation of caspase-9/CASP9 and allowing apoptosome formation (PubMed:18439902). In addition, plays a role in the modulation of histone acetylation and transcription as part of the INHAT (inhibitor of histone acetyltransferases) complex. Inhibits the histone-acetyltranferase activity of EP300/CREBBP (CREB-binding protein) and EP300/CREBBP-associated factor by histone masking (PubMed:11830591). Preferentially binds to unmodified histone H3 and sterically inhibiting its acetylation and phosphorylation leading to cell growth inhibition (PubMed:16341127). Participates in other biochemical processes such as regulation of mRNA nuclear-to-cytoplasmic translocation and stability by its association with ELAVL1 (Hu-antigen R) (PubMed:18180367). Plays a role in E4F1-mediated transcriptional repression as well as inhibition of protein phosphatase 2A (PubMed:15642345, PubMed:17557114)

The "ANP32A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANP32A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets